Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

37 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
Sebestjen M, Zegura B, Guzic-Salobir B, Keber I. Sebestjen M, et al. Wien Klin Wochenschr. 2001 Feb 15;113(3-4):113-8. Wien Klin Wochenschr. 2001. PMID: 11253736
Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia.
Sebestjen M, Zegura B, Keber I. Sebestjen M, et al. J Intern Med. 2002 Jan;251(1):77-85. doi: 10.1046/j.1365-2796.2002.00928.x. J Intern Med. 2002. PMID: 11851868 Clinical Trial.
Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
Sebestjen M, Boh M, Keber I. Sebestjen M, et al. Wien Klin Wochenschr. 2002 Dec 30;114(23-24):999-1003. Wien Klin Wochenschr. 2002. PMID: 12635468 Clinical Trial.
Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis.
Zegura B, Keber I, Sebestjen M, Koenig W. Zegura B, et al. Among authors: sebestjen m. Atherosclerosis. 2003 May;168(1):123-9. doi: 10.1016/s0021-9150(03)00088-1. Atherosclerosis. 2003. PMID: 12732395 Clinical Trial.
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Sebestjen M, Keber I, Zegura B, Simcic S, Bozic M, Fressart MM, Stegnar M. Sebestjen M, et al. Thromb Haemost. 2004 Nov;92(5):1129-35. doi: 10.1160/TH03-04-0250. Thromb Haemost. 2004. PMID: 15543343 Clinical Trial.
Determinants of endothelial dysfunction and carotid intima-media thickness in combined hyperlipidemia.
Sebestjen M, Zegura B, Videcnik V, Keber I. Sebestjen M, et al. Coron Artery Dis. 2005 May;16(3):175-80. doi: 10.1097/00019501-200505000-00007. Coron Artery Dis. 2005. PMID: 15818087
Endothelial function is impaired in patients with primary antiphospholipid syndrome.
Stalc M, Poredos P, Peternel P, Tomsic M, Sebestjen M, Kveder T. Stalc M, et al. Among authors: sebestjen m. Thromb Res. 2006;118(4):455-61. doi: 10.1016/j.thromres.2005.09.005. Epub 2005 Nov 7. Thromb Res. 2006. PMID: 16274735
Inflammation markers in young post-myocardial patients exhibiting various expressions of classic coronary risk factors.
Erzen B, Sabovic M, Poredos P, Sebestjen M, Keber I, Simcic S. Erzen B, et al. Among authors: sebestjen m. Coron Artery Dis. 2006 May;17(4):325-30. doi: 10.1097/00019501-200606000-00001. Coron Artery Dis. 2006. PMID: 16707954
Role of endothelial function and inflammation in patients with cardiovascular risk factors, with and without a history of myocardial infarction.
Sebestjen M, Sabovic M, Erzen B, Simcic S, Zegura B, Poredos P, Keber I. Sebestjen M, et al. Cardiology. 2007;107(1):1-7. doi: 10.1159/000093573. Epub 2006 May 24. Cardiology. 2007. PMID: 16735792
The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. Zegura B, et al. Among authors: sebestjen m. Menopause. 2006 Jul-Aug;13(4):643-50. doi: 10.1097/01.gme.0000198485.70703.7a. Menopause. 2006. PMID: 16837886 Clinical Trial.
37 results
Jump to page
Feedback